Lung cancer and melanoma patients immunized with this formula doubled their chances of surviving three years, according to a ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo –– ...

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Tiragolumab plus atezolizumab did not improve progression-free survival compared to durvalumab in stage III NSCLC patients post-cCRT. Median progression-free survival and overall survival were similar ...

Discusses Business Transformation Strategy and Plans for Accelerated Growth October 16, 2025 5:00 PM EDTCompany ParticipantsXi-Yong Fu ...